| For: | Panuganti VK, Alluri CV, Mohammad J, Dundigalla MR, Madala PK, KSSVV S, Shaik A. Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients. World J Hepatol 2025; 17(12): 113658 [PMID: 41479524 DOI: 10.4254/wjh.v17.i12.113658] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i12/113658.htm |
| Number | Citing Articles |
| 1 |
Haoze Yang, Xuyao Zhang, Dan Zhou, Jing Zou, Lei Xu, Meihan Chen, Siyu Zhao, Jiaxuan Dai, Xiaoming Wang, Xi Du, Jia Liu, Yuhong Huang, Guixiang Pan. Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology. Biochemical Pharmacology 2026; 252 doi: 10.1016/j.bcp.2026.118225
|
| 2 |
Chun-Ye Zhang, Ming Yang. Emerging treatment options for metabolic dysfunction-associated steatotic liver disease and its related liver diseases. World Journal of Hepatology 2026; 18(6): 120178 doi: 10.4254/wjh.120178
|
| 3 |
Nor-ursodeoxycholic Acid for Metabolic Dysfunction-associated Steatotic Liver Disease: Is There Enough Evidence for Clinical Use? A Critique of a Phase III Trial and Regulatory Endorsement of the Drug. Journal of Clinical and Experimental Hepatology 2026; 16(4) doi: 10.1016/j.jceh.2026.103536
|
| 4 |
Qian-Qian Wu, Le-Ying Gao, Hui-Yi Feng, Hao-Lin Liu, Hui Gao, Wei Peng, Nan Li. Regulation of bile acids homeostasis: a feasible and versatile way to treat or diagnose liver disorders. Frontiers in Nutrition 2026; 13 doi: 10.3389/fnut.2026.1797381
|